NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...
FDA fast tracks NKGen's Alzheimer's therapy troculeucel
SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market ...
NKGen Biotech announces publication of Phase 1 troculeucel trial results
NKGen Biotech (NKGN) announced the publication of results from the Company’s initial dose escalation Phase 1 clinical trial of troculeucel, an ...
Study reveals immune system's crucial role in amyotrophic lateral sclerosis at cellular level
A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...
Natural killer cells offer hope for hard-to-treat pediatric sarcomas
University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...
News Medical29d
CAR-NK cells offer safer, more accessible treatment for lymphoma
For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue - called induced pluripotent stem cells (iPSCs) - to make therapeutic CAR-NK cells.
Monthly Prescribing Reference1d
Troculeucel Gets Fast Track Status for Moderate Alzheimer Disease
The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.
Armed robbery in Revesby10h
Research Unveils Immune System's Key Role in ALS
A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...
Life Science Leader8d
Companies To Watch: Senti Bio
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...